Chimeric antigen receptor T cells (CAR T cells) represent an exciting new area of cellular therapy. Manufacturing autologous CAR T cells involves virally transducing a patient’s T cells to express a receptor to heighten recognition of tumor-specific antigens. From a regulatory standpoint, CAR T cells are subject to regulation both as a drug and as a biological product. This presents ongoing challenges for cellular therapy programs and laboratories that seek to develop in-house manufacturing of next-generation CAR T cell products.
|Ashley Krull, Ph.D.
Fellow, Cellular Therapy
|Allan Dietz, Ph.D.
Consultant, Transfusion Medicine
Associate Professor of Laboratory Medicine and Pathology
Instructor in Biochemistry and Molecular Biology
Mayo Clinic College of Medicine and Science